Vic opposition claims synchrotron cost blow-out
05 September, 2003 by Melissa TrudingerPolitical sparring over the Australian National Synchrotron raised its head again last week, when Victoria's opposition deputy leader Phil Honeywood claimed that the project would cost the state AUD$537 million over the next decade, and called the project a white elephant.
More biotechs join S&P300 index
05 September, 2003 by Iain ScottMarket analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index.
Researchers get a preview of synchrotron-based medical opportunities
05 September, 2003 by Melissa TrudingerMore than 130 scientists and clinicians got a glimpse of synchrotron-based medicine at a recent workshop held at the Peter MacCallum Cancer Centre in Melbourne.
Cerylid regroups, lays off staff
04 September, 2003 by Melissa TrudingerUnlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff.
Compumedics revenues, losses up
03 September, 2003 by Melissa TrudingerCompumedics' (ASX:CMP) revenues for the 2002-2003 financial year were up 62 per cent to AUD$32 million, reflecting strong growth in the company's sleep diagnostics business.
Compumedics CEO earns entrepreneur award
26 August, 2003 by Melissa TrudingerCompumedics CEO David Burton has received an Entrepreneur of the Year award from global accounting firm Ernst and Young.
Gradipore board recruits former Sirtex CEO
26 August, 2003 by Melissa TrudingerFormer Sirtex Medical CEO Dr Colin Sutton has joined the board of Gradipore as a non-executive director.
Placement nets $10m for GTG
25 August, 2003 by Melissa TrudingerGenetic Technologies (ASX:GTG) has raised AUD$10 million in a share placement to institutional and professional investors, managed by Sydney boutique investment bank EG Capital.
PwC gives the nod to a biotech bounce
20 August, 2003 by Jeremy TorrA just-released BioForum report by business watchers PricewaterhouseCoopers has talked up the life sciences sector, based on a strong Q4 performance and positive investor sentiment thanks to better than average results compared to the five previous quarters.
Intel eyes the bio network
15 August, 2003 by Jeremy TorrThere are four big targets for computer companies when it comes to networked and clustered computers: energy; manufacturing, financial services – and bioinformatics, according to John Davies, general manager of eBiz channels and marketing at Intel.
Biotech a healthy market for chips
15 August, 2003 by Jeremy TorrIntel is looking hard at the emerging market of biotech devices.
Former BioComm VP moves to Select
08 August, 2003 by Melissa TrudingerDr Anthony Filippis, formerly of BioComm, has joined recently listed Select Vaccines as VP of business development.
Former Coles CEO joins Starpharma board
08 August, 2003 by Melissa TrudingerStarpharma has appointed prominent Melbourne businessman Peter Bartels as a director and chairman of its board of directors, replacing Richard Oliver, who has retired.
Expat to lead UK firms to AusBiotech conference
07 August, 2003 by Melissa TrudingerDelegates from 10 UK biotechnology companies will attend the upcoming AusBiotech 2003 conference in Adelaide, led by expatriate Australian Dr John Sime, currently the director of research support and development at Imperial College, London.
Sirtex records massive result, but Gray warns of slowdown
06 August, 2003 by Melissa TrudingerSirtex Medical has reported an increase in revenues of 1368 per cent, recording more than AUD$10 million in revenues for the 12 months ending June 30, and an after-tax profit of $3.15 million.
